Jump to content

Luteinizing hormone

From Wikipedia, the free encyclopedia
(Redirected from Ovulation prediction kit)

Chorionic Luteinizing hormone alpha
Identifiers
SymbolCGA
Alt. symbolsHCG, GPHa, GPHA1
NCBI gene1081
HGNC1885
OMIM118850
RefSeqNM_000735
UniProtP01215
Other data
LocusChr. 6 q14-q21
Search for
StructuresSwiss-model
DomainsInterPro
Luteinizing hormone beta polypeptide
Identifiers
SymbolLHB
NCBI gene3972
HGNC6584
OMIM152780
RefSeqNM_000894
UniProtP01229
Other data
LocusChr. 19 q13.3
Search for
StructuresSwiss-model
DomainsInterPro

Luteinizing hormone (LH, also known as luteinising hormone,[1] lutropin and sometimes lutrophin[2]) is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus.[3] In females, an acute rise of LH known as an LH surge, triggers ovulation[4] and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH),[5] it stimulates Leydig cell production of testosterone.[4] It acts synergistically with follicle-stimulating hormone (FSH).

Etymology

[edit]

The term luteinizing comes from the Latin "luteus", meaning "yellow". This is in reference to the corpus luteum, which is a mass of cells that forms in an ovary after an ovum (egg) has been discharged. The corpus luteum is so named because it often has a distinctive yellow color. The process of forming the corpus luteum is known as "luteinization", and thus the hormone that triggers this process is termed the "luteinizing" hormone.

Structure

[edit]

LH is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule; one alpha and one beta subunit make the full, functional protein.

Its structure is similar to that of the other glycoprotein hormones, follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG). The protein dimer contains 2 glycopeptidic subunits (labeled alpha- and beta- subunits) that are non-covalently associated:[6]

  • The alpha subunits of LH, FSH, TSH, and hCG are identical, and contain 92 amino acids in human but 96 amino acids in almost all other vertebrate species (glycoprotein hormones do not exist in invertebrates).
  • The beta subunits vary. LH has a beta subunit of 120 amino acids (LHB) that confers its specific biologic action and is responsible for the specificity of the interaction with the LH receptor. This beta subunit contains an amino acid sequence that exhibits large homologies with that of the beta subunit of hCG and both stimulate the same receptor. However, the hCG beta subunit contains an additional 24 amino acids, and the two hormones differ in the composition of their sugar moieties.

The different composition of these oligosaccharides affects bioactivity and speed of degradation. The biologic half-life of LH is 20 minutes, shorter than that of FSH (3–4 hours) and hCG (24 hours).[citation needed] The biological half-life of LH is 23 hours subcutaneous[7] or terminal half life of 10-12 hours.[8]

Genes

[edit]

The gene for the alpha subunit is located on chromosome 6q12.21.

The luteinizing hormone beta subunit gene is localized in the LHB/CGB gene cluster on chromosome 19q13.32. In contrast to the alpha gene activity, beta LH subunit gene activity is restricted to the pituitary gonadotropic cells. It is regulated by the gonadotropin-releasing hormone from the hypothalamus. GnRH activates Egr1 which interacts with transcription factors NR5A1 and PITX1 at the gene promoter to up-regulate LHB transcription.[9][10]

Function

[edit]
Effects of LH on the body

In both males and females, LH works upon endocrine cells in the gonads to produce androgens.

Effects in females

[edit]

LH supports theca cells in the ovaries that provide androgens and hormonal precursors for estradiol production. At the time of menstruation, FSH initiates follicular growth, specifically affecting granulosa cells.[11] With the rise in estrogens, LH receptors are also expressed on the maturing follicle, which causes it to produce more estradiol. Eventually, when the follicle has fully matured, a spike in 17α-hydroxyprogesterone production by the follicle inhibits the production of estrogens. Previously, the preovulatory LH surge was attributed to a decrease in estrogen-mediated negative feedback of GnRH in the hypothalamus, subsequently stimulating the release of LH from the anterior pituitary.[12] Some studies, however, attribute the LH surge to positive feedback from estradiol after production by the dominant follicle exceeds a certain threshold. Exceptionally high levels of estradiol induce hypothalamic production of progesterone, which stimulates elevated GnRH secretion, triggering a surge in LH.[13] The increase in LH production only lasts for 24 to 48 hours. This "LH surge" triggers ovulation, thereby not only releasing the egg from the follicle, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possible implantation. LH is necessary to maintain luteal function for the second two weeks of the menstrual cycle. If pregnancy occurs, LH levels will decrease, and luteal function will instead be maintained by the action of hCG (human chorionic gonadotropin), a hormone very similar to LH but secreted from the new placenta.

Gonadal steroids (estrogens and androgens) generally have negative feedback effects on GnRH-1 release at the level of the hypothalamus and at the gonadotropes, reducing their sensitivity to GnRH. Positive feedback by estrogens also occurs in the gonadal axis of female mammals and is responsible for the midcycle surge of LH that stimulates ovulation. Although estrogens inhibit kisspeptin (Kp) release from kiss1 neurons in the ARC, estrogens stimulate Kp release from the Kp neurons in the AVPV. As estrogens' levels gradually increase the positive effect predominates, leading to the LH surge. GABA-secreting neurons that innervate GnRH-1 neurons also can stimulate GnRH-1 release. These GABA neurons also possess ERs and may be responsible for the GnRH-1 surge. Part of the inhibitory action of endorphins on GnRH-1 release is through inhibition of these GABA neurons. Rupture of the ovarian follicle at ovulation causes a drastic reduction in estrogen synthesis and a marked increase in secretion of progesterone by the corpus luteum in the ovary, reinstating a predominantly negative feedback on hypothalamic secretion of GnRH-1.[14]

Effects in males

[edit]

LH acts upon the Leydig cells of the testis and is regulated by gonadotropin-releasing hormone (GnRH).[15] The Leydig cells produce testosterone under the control of LH. LH binds to LH receptors on the membrane surface of Leydig cells. Binding to this receptor causes an increase in cyclic adenosine monophosphate (cAMP), a secondary messenger, which allows cholesterol to translocate into the mitochondria. Within the mitochondria, cholesterol is converted to pregnenolone by CYP11A1.[16] Pregnenolone is then converted to dehydroepiandrosterone (DHEA).[17] DHEA is then converted to androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD)[18] and then finally converted to testosterone by 17β-hydroxysteroid dehydrogenase (HSD17B). The onset of puberty is controlled by two major hormones: FSH initiates spermatogenesis and LH signals the release of testosterone,[19] an androgen that exerts both endocrine activity and intratesticular activity on spermatogenesis.

LH is released from the pituitary gland, and is controlled by pulses of gonadotropin-releasing hormone. When bloodstream testosterone levels are low, the pituitary gland is stimulated to release LH.[15] As the levels of testosterone increase, it will act on the pituitary through a negative feedback loop and inhibit the release of GnRH and LH consequently.[20] Androgens (including testosterone and dihydrotestosterone) inhibit monoamine oxidase (MAO) in the pineal gland, leading to increased melatonin and reduced LH and FSH by melatonin-induced increase of Gonadotropin-Inhibitory Hormone (GnIH)[21] synthesis and secretion. Testosterone can also be aromatized into estradiol (E2) to inhibit LH. E2 decreases pulse amplitude and responsiveness to GnRH from the hypothalamus onto the pituitary.[22]

Changes in LH and testosterone blood levels and pulse secretions are induced by changes in sexual arousal in human males.[23]

Effects in the brain

[edit]

Luteinizing hormone receptors are located in areas of the brain associated with cognitive function.[24] The role of LH role in the central nervous system (CNS) may be of relevance to understanding and treating post-menopausal cognitive decline.[25]

Some research has observed an inverse relationship between circulating LH and CNS LH levels.[26] After ovariectomy (a procedure used to mimic menopause) in female mice, circulating LH levels surge while CNS levels of LH fall.[24] Treatments that lower circulating LH restore LH levels in the CNS.[24]

Normal levels

[edit]
Reference ranges for the blood content of luteinizing hormone (LH) during the menstrual cycle.[27]
  • The ranges denoted By biological stage may be used in closely monitored menstrual cycles in regard to other markers of its biological progression, with the time scale being compressed or stretched to how much faster or slower, respectively, the cycle progresses compared to an average cycle.
  • The ranges denoted Inter-cycle variability are more appropriate to use in non-monitored cycles with only the beginning of menstruation known, but where the woman accurately knows her average cycle lengths and time of ovulation, and that they are somewhat averagely regular, with the time scale being compressed or stretched to how much a woman's average cycle length is shorter or longer, respectively, than the average of the population.
  • The ranges denoted Inter-woman variability are more appropriate to use when the average cycle lengths and time of ovulation are unknown, but only the beginning of menstruation is given.

LH levels are normally low during childhood and in women, high after menopause. Since LH is secreted as pulses, it is necessary to follow its concentration over a sufficient period of time to get proper information about its blood level.

During reproductive years, typical levels are between 1 and 20 IU/L. Physiologic high LH levels are seen during the LH surge (v.s.) and typically last 48 hours.

In males over 18 years of age, reference ranges have been estimated to be 1.8–8.6 IU/L.[28]

LH is measured in international units (IU). When quantifying the amount of LH in a sample in IUs, it is important to know which international standard your lot of LH was calibrated against since they can vary broadly from year to year. For human urinary LH, one IU is defined as 1/189th of an ampule denoted 96/602 and distributed by the NIBSC, corresponding to approximately 0.04656 μg of LH protein for a single IU, but older standard versions are still widely in use.[29][30]

Lateral flow test strip for urine LH, used to predict ovulation

Predicting ovulation

[edit]
Chance of fertilization by menstrual cycle day relative to ovulation[31]

The detection of a surge in release of luteinizing hormone indicates impending ovulation. LH can be detected by urinary ovulation predictor kits (OPK, also LH-kit) that are performed, typically daily, around the time ovulation may be expected.[32] A conversion from a negative to a positive reading would suggest that ovulation is about to occur within 24–48 hours, giving women two days to engage in sexual intercourse or artificial insemination with the intention of conceiving.[33]

The recommended testing frequency differs between manufacturers. For example, the Clearblue test is taken daily, and an increased frequency does not decrease the risk of missing an LH surge.[34] On the other hand, the Chinese company Nantong Egens Biotechnology recommends using their test twice per day.[35] If testing once per day, no significant difference has been found between testing LH in the morning versus in the evening, in relation to conception rates,[36] and recommendations of what time in the day to take the test varies between manufacturers and healthcare workers.[37] Tests may be read manually using a color-change paper strip, or digitally with the assistance of reading electronics.

Tests for luteinizing hormone may be combined with testing for estradiol in tests such as the Clearblue fertility monitor.[medical citation needed]

The sensitivity of LH tests are measured in milli international unit, with tests commonly available in the range 10–40 m.i.u. (the lower the number, the higher the sensitivity).[citation needed]

As sperm can stay viable in the woman for several days, LH tests are not recommended for contraceptive practices, as the LH surge typically occurs after the beginning of the fertile window.[citation needed]

Disease states

[edit]

Excess

[edit]

In children with precocious puberty of pituitary or central origin, LH and FSH levels may be in the reproductive range instead of the low levels typical for their age.

During the reproductive years, relatively elevated LH is frequently seen in patients with polycystic ovary syndrome; however, it would be unusual for them to have LH levels outside of the normal reproductive range.

Persistently high LH levels are indicative of situations where the normal restricting feedback from the gonad is absent, leading to a pituitary production of both LH and FSH. While this is typical in menopause, it is abnormal in the reproductive years. There it may be a sign of:

  1. Premature menopause
  2. Gonadal dysgenesis, Turner syndrome, Klinefelter syndrome
  3. Castration
  4. Swyer syndrome
  5. Polycystic ovary syndrome
  6. Certain forms of congenital adrenal hyperplasia
  7. Testicular failure
  8. Pregnancy – BetaHCG can mimic LH so tests may show elevated LH

Note: A medical drug for inhibiting luteinizing hormone secretion is butinazocine.[38]

Deficiency

[edit]

Diminished secretion of LH can result in failure of gonadal function (hypogonadism). This condition is typically manifest in males as failure in production of normal numbers of sperm. In females, amenorrhea is commonly observed. Conditions with very low LH secretions include:

  1. Pasqualini syndrome[39][40]
  2. Kallmann syndrome
  3. Hypothalamic suppression
  4. Hypopituitarism
  5. Eating disorder
  6. Female athlete triad
  7. Hyperprolactinemia
  8. Hypogonadism
  9. Gonadal suppression therapy
    1. GnRH antagonist
    2. GnRH agonist (inducing an initial stimulation (flare up) followed by permanent blockage of the GnRH pituitary receptor)

As a medication

[edit]
Luteinizing hormone
INN: lutropin alfa
Clinical data
ATC code
Legal status
Legal status
Identifiers
CAS Number
UNII
ECHA InfoCard100.029.680 Edit this at Wikidata

Luteinizing hormone is available mixed with FSH in the form of menotropin, and other forms of urinary gonadotropins. More purified forms of urinary gonadotropins may reduce the LH portion in relation to FSH. Recombinant luteinizing hormone is available as lutropin alfa (Luveris).[41]

Role in phosphorylation

[edit]

Phosphorylation is a biochemical process that involves the addition of phosphate to an organic compound. Steroidogenesis entails processes by which cholesterol is converted to biologically active steroid hormones. A study shows that LH via a PKA signaling pathway regulates the phosphorylation and localization of DRP1 within mitochondria of the steroidogenic cells of the ovary.[42]

References

[edit]
  1. ^ GCSE Science Revision Biology "The Menstrual Cycle", 17 April 2018, retrieved 23 March 2022
  2. ^ Ujihara M, Yamamoto K, Nomura K, Toyoshima S, Demura H, Nakamura Y, et al. (June 1992). "Subunit-specific sulphation of oligosaccharides relating to charge-heterogeneity in porcine lutrophin isoforms". Glycobiology. 2 (3): 225–231. doi:10.1093/glycob/2.3.225. PMID 1498420.
  3. ^ Stamatiades GA, Kaiser UB (March 2018). "Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression". Molecular and Cellular Endocrinology. Signaling Pathways Regulating Pituitary Functions. 463: 131–141. doi:10.1016/j.mce.2017.10.015. PMC 5812824. PMID 29102564.
  4. ^ a b Nosek TM. "Section 5/5ch9/s5ch9_5". Essentials of Human Physiology. Archived from the original on 24 March 2016.
  5. ^ Louvet JP, Harman SM, Ross GT (May 1975). "Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats". Endocrinology. 96 (5): 1179–1186. doi:10.1210/endo-96-5-1179. PMID 1122882.
  6. ^ Jiang X, Dias JA, He X (January 2014). "Structural biology of glycoprotein hormones and their receptors: insights to signaling". Molecular and Cellular Endocrinology. 382 (1): 424–451. doi:10.1016/j.mce.2013.08.021. PMID 24001578.
  7. ^ Ezcurra D, Humaidan P (October 2014). "A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology". Reproductive Biology and Endocrinology. 12 (1): 95. doi:10.1186/1477-7827-12-95. PMC 4287577. PMID 25280580.
  8. ^ le Cotonnec JY, Porchet HC, Beltrami V, Munafo A (February 1998). "Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone". Fertility and Sterility. 69 (2): 189–194. doi:10.1016/S0015-0282(97)00501-3. PMID 9496327.
  9. ^ Tremblay JJ, Drouin J (April 1999). "Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription". Molecular and Cellular Biology. 19 (4): 2567–2576. doi:10.1128/MCB.19.4.2567. PMC 84049. PMID 10082522.
  10. ^ Dorn C, Ou Q, Svaren J, Crawford PA, Sadovsky Y (May 1999). "Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1". The Journal of Biological Chemistry. 274 (20): 13870–13876. doi:10.1074/jbc.274.20.13870. PMID 10318795.
  11. ^ Bowen R (13 May 2004). "Gonadotropins: Luteinizing and Follicle Stimulating Hormones". Colorado State University. Retrieved 12 March 2012.[dead link‍]
  12. ^ Mahesh VB (January 2012). "Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective". American Journal of Physiology. Endocrinology and Metabolism. 302 (1): E4–E18. doi:10.1152/ajpendo.00488.2011. PMC 3328092. PMID 22028409.
  13. ^ Micevych P, Sinchak K (2 December 2011). "The Neurosteroid Progesterone Underlies Estrogen Positive Feedback of the LH Surge". Frontiers in Endocrinology. 2: 90. doi:10.3389/fendo.2011.00090. PMC 3356049. PMID 22654832.
  14. ^ Norris DO, Carr JA (2013). Vertebrate Endocrinology. Academic Press. p. 126. ISBN 978-0-12-396465-6.
  15. ^ a b Nedresky D, Singh G (September 2022). "Physiology, Luteinizing Hormone". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30969514.
  16. ^ Zirkin BR, Papadopoulos V (July 2018). "Leydig cells: formation, function, and regulation". Biology of Reproduction. 99 (1): 101–111. doi:10.1093/biolre/ioy059. PMC 6044347. PMID 29566165.
  17. ^ Akhtar MK, Kelly SL, Kaderbhai MA (November 2005). "Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis". The Journal of Endocrinology. 187 (2): 267–274. doi:10.1677/joe.1.06375. PMID 16293774.
  18. ^ Liu L, Kang J, Ding X, Chen D, Zhou Y, Ma H (2015). "Dehydroepiandrosterone-Regulated Testosterone Biosynthesis via Activation of the ERK1/2 Signaling Pathway in Primary Rat Leydig Cells". Cellular Physiology and Biochemistry. 36 (5): 1778–1792. doi:10.1159/000430150. PMID 26184424. S2CID 13816368.
  19. ^ Oduwole OO, Peltoketo H, Huhtaniemi IT (2018). "Role of Follicle-Stimulating Hormone in Spermatogenesis". Frontiers in Endocrinology. 9: 763. doi:10.3389/fendo.2018.00763. PMC 6302021. PMID 30619093.
  20. ^ Tilbrook AJ, Clarke IJ (March 2001). "Negative feedback regulation of the secretion and actions of gonadotropin-releasing hormone in males". Biology of Reproduction. 64 (3): 735–742. doi:10.1095/biolreprod64.3.735. PMID 11207186.
  21. ^ Ubuka T, Son YL, Tobari Y, Narihiro M, Bentley GE, Kriegsfeld LJ, et al. (2014). "Central and direct regulation of testicular activity by gonadotropin-inhibitory hormone and its receptor". Frontiers in Endocrinology. 5: 8. doi:10.3389/fendo.2014.00008. PMC 3902780. PMID 24478760.
  22. ^ Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF, et al. (March 2008). "Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men". The Journal of Clinical Endocrinology and Metabolism. 93 (3): 784–791. doi:10.1210/jc.2007-2156. PMC 2266963. PMID 18073301.
  23. ^ Stoléru SG, Ennaji A, Cournot A, Spira A (1993). "LH pulsatile secretion and testosterone blood levels are influenced by sexual arousal in human males". Psychoneuroendocrinology. 18 (3): 205–218. doi:10.1016/0306-4530(93)90005-6. PMID 8516424. S2CID 23595343.
  24. ^ a b c Blair JA, Bhatta S, McGee H, Casadesus G (November 2015). "Luteinizing hormone: Evidence for direct action in the CNS". Hormones and Behavior. 76: 57–62. doi:10.1016/j.yhbeh.2015.06.020. PMC 4741372. PMID 26172857.
  25. ^ Than S, Moran C, Beare R, Vincent A, Lane E, Collyer TA, et al. (2023). "Cognitive trajectories during the menopausal transition". Frontiers in Dementia. 2. doi:10.3389/frdem.2023.1098693. ISSN 2813-3919. PMC 11285668. PMID 39081973.
  26. ^ Bhatta S, Blair JA, Casadesus G (24 September 2018). "Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss". Frontiers in Endocrinology. 9: 544. doi:10.3389/fendo.2018.00544. PMC 6165885. PMID 30319538.
  27. ^ Häggström M (2014). "Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.001. ISSN 2002-4436.
  28. ^ "Test ID: LH, Luteinizing Hormone (LH), Serum". Mayo Medical Laboratories. Archived from the original on 25 September 2016. Retrieved 1 December 2012.
  29. ^ WHO Expert Committee on Biological Standardization (2003). "Proposed International Standard for Luteinizing Hormone" (PDF). Geneva: World Health Organization.
  30. ^ "WHO International Standard, Luteinizing Hormone, Human, Recombinant" (PDF). National Institute for Biological Standards and Control.
  31. ^ Dunson DB, Baird DD, Wilcox AJ, Weinberg CR (July 1999). "Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation". Human Reproduction. 14 (7): 1835–1839. doi:10.1093/humrep/14.7.1835. PMID 10402400.
  32. ^ Nielsen MS, Barton SD, Hatasaka HH, Stanford JB (August 2001). "Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick". Fertility and Sterility. 76 (2): 384–387. doi:10.1016/S0015-0282(01)01881-7. PMID 11476792.
  33. ^ "Ovulation Predictor Kit Frequently Asked Questions". Fertility Plus. Archived from the original on 12 March 2012. Retrieved 12 March 2012.[unreliable medical source?]
  34. ^ "Clear Blue Ovulation Test Instructions". Ovulation Guide. Retrieved 19 January 2018.
  35. ^ "Advanced Ovulation Test" (PDF). Homehealth-UK. Retrieved 19 January 2018. Version 1.1 02/11/15
  36. ^ Martinez AR, Bernardus RE, Vermeiden JP, Schoemaker J (March 1994). "Time schedules of intrauterine insemination after urinary luteinizing hormone surge detection and pregnancy results". Gynecological Endocrinology. 8 (1): 1–5. doi:10.3109/09513599409028450. PMID 8059611.
  37. ^ Meniru GI (2001). Cambridge Guide to Infertility Management and Assisted Reproduction. Cambridge University Press. p. 67.
  38. ^ US 4406904, Welle HB, Marko M, "Method of inhibiting luteinizing hormone secretion with 6,7-benzomorphan derivatives", issued 27 September 1983, assigned to ACF Chemiefarma NV. 
  39. ^ Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL (January 1992). "Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone". The New England Journal of Medicine. 326 (3): 179–183. doi:10.1056/NEJM199201163260306. PMID 1727547.
  40. ^ Valdes-Socin H, Salvi R, Daly AF, Gaillard RC, Quatresooz P, Tebeu PM, et al. (December 2004). "Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene". The New England Journal of Medicine. 351 (25): 2619–2625. doi:10.1056/NEJMoa040326. hdl:2268/23485. PMID 15602022.
  41. ^ a b "Luveris EPAR". European Medicines Agency. 29 November 2000. Retrieved 23 July 2024.
  42. ^ Plewes MR, Hou X, Talbott HA, Zhang P, Wood JR, Cupp AS, et al. (April 2020). "Luteinizing hormone regulates the phosphorylation and localization of the mitochondrial effector dynamin-related protein-1 (DRP1) and steroidogenesis in the bovine corpus luteum". FASEB Journal. 34 (4). Federation of American Societies for Experimental Biology: 5299–5316. doi:10.1096/fj.201902958R. PMC 7136153. PMID 32077149.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Luteinizing_hormone&oldid=1263228537#Predicting_ovulation"